Get Premium to unlock powerful stock data

Baker Bros. Advisors Lp Buys Ascendis Pharma A/S, Pacific Biosciences of California Inc, Travere Therapeutics Inc, Sells Apellis Pharmaceuticals Inc, ADC Therapeutics SA, Protagonist Therapeutics Inc

Author's Avatar
insider
Nov 17, 2021
Article's Main Image
New York, NY, based Investment company Baker Bros. Advisors Lp (Current Portfolio) buys Ascendis Pharma A/S, Pacific Biosciences of California Inc, Travere Therapeutics Inc, Legend Biotech Corp, Kymera Therapeutics Inc, sells Apellis Pharmaceuticals Inc, ADC Therapeutics SA, Protagonist Therapeutics Inc, Assembly Biosciences Inc, IVERIC bio Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Baker Bros. Advisors Lp. As of 2021Q3, Baker Bros. Advisors Lp owns 117 stocks with a total value of $22.6 billion. These are the details of the buys and sells.

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to https://www.gurufocus.com/guru/baker+bros.+advisors+lp/current-portfolio/portfolio

These are the top 5 holdings of BAKER BROS. ADVISORS LP
  1. Seagen Inc (SGEN) - 47,288,259 shares, 35.56% of the total portfolio.
  2. BeiGene Ltd (BGNE) - 11,668,897 shares, 18.76% of the total portfolio.
  3. Incyte Corp (INCY) - 32,022,125 shares, 9.75% of the total portfolio.
  4. Kodiak Sciences Inc (KOD) - 14,681,304 shares, 6.24% of the total portfolio. Shares added by 3.84%
  5. Ascendis Pharma A/S (ASND) - 4,541,604 shares, 3.21% of the total portfolio. Shares added by 28.28%
New Purchase: DICE Therapeutics Inc (DICE)

Baker Bros. Advisors Lp initiated holding in DICE Therapeutics Inc. The purchase prices were between $31.92 and $37, with an estimated average price of $34.06. The stock is now traded at around $34.150000. The impact to a portfolio due to this purchase was 0.09%. The holding were 588,235 shares as of 2021-09-30.

New Purchase: Surrozen Inc (SRZN)

Baker Bros. Advisors Lp initiated holding in Surrozen Inc. The purchase prices were between $6.98 and $12.03, with an estimated average price of $8.91. The stock is now traded at around $9.510000. The impact to a portfolio due to this purchase was 0.08%. The holding were 2,500,000 shares as of 2021-09-30.

New Purchase: TScan Therapeutics Inc (TCRX)

Baker Bros. Advisors Lp initiated holding in TScan Therapeutics Inc. The purchase prices were between $6.17 and $13.48, with an estimated average price of $9.26. The stock is now traded at around $8.510000. The impact to a portfolio due to this purchase was 0.05%. The holding were 1,425,000 shares as of 2021-09-30.

New Purchase: Tango Therapeutics Inc (TNGX)

Baker Bros. Advisors Lp initiated holding in Tango Therapeutics Inc. The purchase prices were between $9.56 and $17.3, with an estimated average price of $13.13. The stock is now traded at around $13.500000. The impact to a portfolio due to this purchase was 0.04%. The holding were 750,000 shares as of 2021-09-30.

New Purchase: Amryt Pharma PLC (AMYT)

Baker Bros. Advisors Lp initiated holding in Amryt Pharma PLC. The purchase prices were between $9.63 and $12.47, with an estimated average price of $11.29. The stock is now traded at around $11.170000. The impact to a portfolio due to this purchase was 0.03%. The holding were 518,380 shares as of 2021-09-30.

New Purchase: aTyr Pharma Inc (LIFE)

Baker Bros. Advisors Lp initiated holding in aTyr Pharma Inc. The purchase prices were between $4.22 and $12.48, with an estimated average price of $5.96. The stock is now traded at around $8.520000. The impact to a portfolio due to this purchase was 0.03%. The holding were 625,000 shares as of 2021-09-30.

Added: Ascendis Pharma A/S (ASND)

Baker Bros. Advisors Lp added to a holding in Ascendis Pharma A/S by 28.28%. The purchase prices were between $112.67 and $176.92, with an estimated average price of $137.27. The stock is now traded at around $157.000000. The impact to a portfolio due to this purchase was 0.71%. The holding were 4,541,604 shares as of 2021-09-30.

Added: Pacific Biosciences of California Inc (PACB)

Baker Bros. Advisors Lp added to a holding in Pacific Biosciences of California Inc by 70.05%. The purchase prices were between $24.86 and $35.02, with an estimated average price of $29.71. The stock is now traded at around $28.060000. The impact to a portfolio due to this purchase was 0.26%. The holding were 5,444,963 shares as of 2021-09-30.

Added: Travere Therapeutics Inc (TVTX)

Baker Bros. Advisors Lp added to a holding in Travere Therapeutics Inc by 991.28%. The purchase prices were between $12.98 and $25.03, with an estimated average price of $18.37. The stock is now traded at around $29.470000. The impact to a portfolio due to this purchase was 0.2%. The holding were 2,039,772 shares as of 2021-09-30.

Added: Legend Biotech Corp (LEGN)

Baker Bros. Advisors Lp added to a holding in Legend Biotech Corp by 42.02%. The purchase prices were between $35.31 and $50.56, with an estimated average price of $41.56. The stock is now traded at around $52.700000. The impact to a portfolio due to this purchase was 0.16%. The holding were 2,364,003 shares as of 2021-09-30.

Added: Kymera Therapeutics Inc (KYMR)

Baker Bros. Advisors Lp added to a holding in Kymera Therapeutics Inc by 21.72%. The purchase prices were between $47.8 and $66.66, with an estimated average price of $57.98. The stock is now traded at around $61.170000. The impact to a portfolio due to this purchase was 0.11%. The holding were 2,384,742 shares as of 2021-09-30.

Added: bluebird bio Inc (BLUE)

Baker Bros. Advisors Lp added to a holding in bluebird bio Inc by 1001.25%. The purchase prices were between $11.24 and $20.99, with an estimated average price of $14.34. The stock is now traded at around $11.580000. The impact to a portfolio due to this purchase was 0.06%. The holding were 2,499,715 shares as of 2021-09-30.

Sold Out: Apellis Pharmaceuticals Inc (APLS)

Baker Bros. Advisors Lp sold out a holding in Apellis Pharmaceuticals Inc. The sale prices were between $31.4 and $69.84, with an estimated average price of $56.51.

Sold Out: ADC Therapeutics SA (ADCT)

Baker Bros. Advisors Lp sold out a holding in ADC Therapeutics SA. The sale prices were between $20.45 and $30, with an estimated average price of $25.62.

Sold Out: Protagonist Therapeutics Inc (PTGX)

Baker Bros. Advisors Lp sold out a holding in Protagonist Therapeutics Inc. The sale prices were between $12.95 and $49.69, with an estimated average price of $42.78.

Sold Out: Assembly Biosciences Inc (ASMB)

Baker Bros. Advisors Lp sold out a holding in Assembly Biosciences Inc. The sale prices were between $3.14 and $3.9, with an estimated average price of $3.49.

Sold Out: IVERIC bio Inc (ISEE)

Baker Bros. Advisors Lp sold out a holding in IVERIC bio Inc. The sale prices were between $7.07 and $17.5, with an estimated average price of $10.82.

Sold Out: Silverback Therapeutics Inc (SBTX)

Baker Bros. Advisors Lp sold out a holding in Silverback Therapeutics Inc. The sale prices were between $9.98 and $35.22, with an estimated average price of $24.7.



Here is the complete portfolio of BAKER BROS. ADVISORS LP. Also check out:

1. BAKER BROS. ADVISORS LP's Undervalued Stocks
2. BAKER BROS. ADVISORS LP's Top Growth Companies, and
3. BAKER BROS. ADVISORS LP's High Yield stocks
4. Stocks that BAKER BROS. ADVISORS LP keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus